Dare Bioscience Inc

NASDAQ:DARE   3:59:59 PM EDT
1.52
-0.10 (-6.48%)
Products, Regulatory

Daré Bioscience Completes Recruitment In Phase 1 Clinical Trial Of Dare-Hrt1

Published: 03/22/2021 12:27 GMT
Dare Bioscience Inc (DARE) - DarÉ Bioscience Completes Recruitment in Phase 1 Clinical Trial of Dare-hrt1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Vasomotor Symptoms and Genitourinary Syndrome Associated With Menopaus.
Dare Bioscience Inc - Anticipates Reporting Topline Data From Dare-hrt1 Study in Q2 of 2021.